Breast Cancer News and Research

Latest Breast Cancer News and Research

Unigene enters agreement with GSK to advance oral PTH Phase 2 program for osteoporosis

Unigene enters agreement with GSK to advance oral PTH Phase 2 program for osteoporosis

Genomic Health announces results of Oncotype DX test in early-stage breast cancer patients

Genomic Health announces results of Oncotype DX test in early-stage breast cancer patients

Nektar reports positive results from NKTR-102 Phase 2 study in metastatic breast cancer at CTRC-AACR SABCS

Nektar reports positive results from NKTR-102 Phase 2 study in metastatic breast cancer at CTRC-AACR SABCS

Lack of strong molecular 'glue' allows tumour cells to break away and spread

Lack of strong molecular 'glue' allows tumour cells to break away and spread

Even small amount of alcohol increases chances of developing cancer

Even small amount of alcohol increases chances of developing cancer

UCSF physicians evlaute devices that could reduce hair loss in breast cancer patients undergoing chemotherapy

UCSF physicians evlaute devices that could reduce hair loss in breast cancer patients undergoing chemotherapy

FOXA1 gene controls oestrogen-fuelled growth of breast cancer cells

FOXA1 gene controls oestrogen-fuelled growth of breast cancer cells

Bionovo reports positive Menerba clinical program meeting with FDA

Bionovo reports positive Menerba clinical program meeting with FDA

PLATO Foundation launches first medical education activity during 33rd CTRC - AACR Symposium

PLATO Foundation launches first medical education activity during 33rd CTRC - AACR Symposium

Strategies for securing life insurance policy for pre-existing medical conditions

Strategies for securing life insurance policy for pre-existing medical conditions

bioTheranostics reports new findings from study evaluating Breast Cancer Index molecular oncology test

bioTheranostics reports new findings from study evaluating Breast Cancer Index molecular oncology test

GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR

GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR

Syndax reports promising results from entinostat preclinical studies in breast cancer

Syndax reports promising results from entinostat preclinical studies in breast cancer

Exemestane may provide post-surgery option for postmenopausal women with hormone-receptor positive breast cancer

Exemestane may provide post-surgery option for postmenopausal women with hormone-receptor positive breast cancer

Combination of SPECT and CT scans could offer protection against lymphedema in breast cancer patients

Combination of SPECT and CT scans could offer protection against lymphedema in breast cancer patients

Do not delay breast cancer therapy during pregnancy

Do not delay breast cancer therapy during pregnancy

First-ever Prophylactic Cancer Vaccine Conference to be held in Tempe, Arizona

First-ever Prophylactic Cancer Vaccine Conference to be held in Tempe, Arizona

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

Scientists demonstrate triple-drug cocktail for triple negative breast cancer at AACR symposium

Scientists demonstrate triple-drug cocktail for triple negative breast cancer at AACR symposium

Higher co-payments lead to early discontinuation of life-saving therapy for breast cancer

Higher co-payments lead to early discontinuation of life-saving therapy for breast cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.